Medical Imaging Drugs Advisory Committee Will Phase Out By March 2004
This article was originally published in The Gray Sheet
Executive Summary
FDA's Medical Imaging Drugs and Pharmacy Compounding advisory committees will terminate after their charters expire in February 2004
You may also be interested in...
New CBER Panel Should Be Established For Combo Products Review – AAOS
A new FDA advisory panel under the purview of the Center for Biologics Evaluation & Research should be created specifically to review combination products, the American Academy of Orthopaedic Surgeons recommends
New CBER Panel Should Be Established For Combo Products Review – AAOS
A new FDA advisory panel under the purview of the Center for Biologics Evaluation & Research should be created specifically to review combination products, the American Academy of Orthopaedic Surgeons recommends
HHS Genetics Panel Replaces SACGT; Thompson Defends Membership Rules
HHS' reconfigured panel on genetics policy places less focus on genetic test regulation than its predecessor, the Secretary's Advisory Committee on Genetic Testing